Clinical Trial Update: Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on clofarabine for recurrent or refractory Langerhans cell histiocytosis with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Langerhans Cell Histiocytosis

Drugs mentioned

• Clofarabine (clofarabine)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Langerhans Cell Histiocytosis | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2022-02-16